Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share (Tables)

6 Months Ended

Jun. 30, 2012


($ in thousands except share and per share amounts)	For the three months ended June 30,						For the six months ended June 30,
($ in thousands except share and per share amounts)	2012			2011			2012			2011

Historical net loss per share:

Numerator:

Net loss	$	(6,455	)	$	(3,733	)	$	(13,011	)	$	(26,276	)

Common Stock dividend to Series A Convertible Preferred Stockholders		—			(5,861	)		—			(5,861	)


Net loss attributed to Common Stock	$	(6,455	)	$	(9,594	)	$	(13,011	)	$	(32,137	)

Denominator:

Weighted average common shares outstanding—basic and diluted		19,194,053			5,848,642			18,899,149			5,322,793


Basic and diluted net loss per common share	$	(0.34	)	$	(1.64	)	$	(0.69	)	$	(6.04	)


	For the three months ended June 30,				For the six months ended June 30,
	2012		2011		2012		2011
Series A Convertible Preferred Stock		—		4,357,885		—		4,357,885
Series B Convertible Preferred Stock		—		2,525,677		—		2,441,953
Series C Convertible Preferred Stock		—		943,870		—		474,542
Warrants to purchase Common Stock		1,042,216		684,671		1,055,509		573,223
Options to purchase Common Stock		2,324,400		1,454,894		2,161,707		1,315,345

		3,366,616		9,966,997		3,217,216		9,162,948